Back
1 min read
[Press Release] The French biotech XENOTHERA, on a mission with business France in China
-
- Author Bertrand Fabien
- Published 21 avril 2023
Related Posts
June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone
Read MoreMay, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…
Read MoreDecember, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….
Read More